Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Insurance Coverage Requested for Candesartan as CHF Treatment
April 12, 2004
- REGULATORY NEWS IN BRIEF
April 12, 2004
- Sales of Bayer HealthCare in Japan Level Last Year: Dr Portoff
April 12, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 12, 2004
- MEDICAL DEVICE NEWS IN BRIEF
April 12, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 12, 2004
- CMIC MPSS Focusing on Subject Recruitment, Education, Training
April 12, 2004
- Sweeping Revision of OTC Drug Marketing Regulations to Be Discussed
April 12, 2004
- Companies Welcome Newcomers
April 12, 2004
- OTC NEWS IN BRRIEF
April 12, 2004
- Informed Choice Better than Informed Consent: JPMA Consumer Survey
April 12, 2004
- Japanese Healthcare Q&A (7)
April 12, 2004
- BUSINESS NEWS IN BRIEF -1-
April 12, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 12, 2004
- BUSINESS NEWS IN BRIEF -2-
April 12, 2004
- WORLD NEWS IN BREIF
April 12, 2004
- Merger Synergism Boosts Chugai's Performances: Mr Nagayama
April 5, 2004
- Gastric Cancer Therapeutic GL to Be Revised
April 5, 2004
- WORLD NEWS IN BRIEF
April 5, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 5, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…